



ESC Declaration of Interest Report 2022 ESC Guidelines on cardio-oncology

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in the development of ESC Guidelines to comply with the *ESC Declaration and Management of Conflict of Interest Policy*. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of the Guidelines.

All DOIs presented in this report were assessed prior to work commencing and during the development of the work, according to the applicable review criteria in place at the time and as defined in the *ESC Declaration and Management of Conflict of Interest Policy, Annex 3*, as approved by the ESC in July 2020.

The most up-to-date version of the policy and its annexes are available on the ESC website at www.escardio.org/DOI.

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Asteggiano Riccardo	<p>2020</p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.For yourself - Springer Nature Switzerland AG, : IB323946 Royalties Earned Current Period Royalties Due 1: Cardiac Management of Oncology Patients Edition 1 266979</p>
	<p>2021</p> <p>Financial Declaration</p> <p>- Council of Cardio-Oncology ESC : cardio-oncology</p>
Aznar Marianne	<p>2020</p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Mirada Medical Ltd, Oxford, UK : Oncology / Radiotherapy</p>
	<p>2021</p> <p>Financial Declaration</p> <p>- Mirada Medical Ltd, Oxford, UK : Oncology / Radiotherapy</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself - member of Physics Committee of the European Society for Radiotherapy and Oncology (ESTRO)</p>
Bergler-Klein Jutta	<p>2020</p> <p>Nothing to be declared</p>
	<p>2021</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Boriani Giuseppe	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer : Anticoagulants - Boston Scientific : Pacemaker, cardioverter defibrillators - Medtronic : Pacemaker, cardioverter defibrillators
	<p>-----</p> <p>2021</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Bayer : Anticoagulants - Daiichi Sankyo : Anticoagulants - Boston Scientific : Pacemaker, cardioverter defibrillators - Medtronic : Pacemaker, cardioverter defibrillators
Cardinale Daniela	<p>2020</p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Siemer Healthcare : CARDIOTOXICITY
	<p>-----</p> <p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Ipsen : Androgen-deprivation therapy and cardiovascular toxicity

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cordoba Raul	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - AbbVie : CLL - Roche Pharma : Lymphoma - Takeda Pharmaceuticals : Lymphoma - Bristol Myers Squibb : Lymphoma - Incyte : Lymphoma - Kite : Lymphoma - Janssen-Cilag : Lymphoma, CLL <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Pfizer : Geriatric Oncology, Lymphoma
	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : CLL - AbbVie : CLL - Janssen-Cilag : Lymphoma - Roche Pharma : Lymphoma - Takeda Pharmaceuticals : Lymphoma - Incyte : Lymphoma - Kite : Lymphoma

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cordoba Raul	<p>2021</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Pfizer : Lymphoma</p>
Cosyns Bernard	<p>2020</p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.For yourself - Oxford University Press : Echocardiography</p>
	<p>2021</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Abbott : unrestricted research grant in the field of interventional cardiology</p>
Couch Liam	<p>2020</p> <p>Nothing to be declared</p>
	<p>2021</p> <p>Nothing to be declared</p>
Cutter David John	<p>2020</p> <p>Nothing to be declared</p>
	<p>2021</p> <p>Nothing to be declared</p>
de Azambuja Evandro	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Novartis : Oncology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
de Azambuja Evandro	<p>2020</p> <ul style="list-style-type: none"> - Lilly : Oncology - Roche Pharma : Oncology - Pierre-Fabre : Oncology - Libbs : Oncology - Seattle Genetics : Oncology - Zodiacs : oncology <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Roche Pharma : clinical research oncology - Astra Zeneca : clinical trials oncology - Novartis : clinical trials oncology - Servier : clinical trials oncology <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Roche Pharma : Oncology
De Boer Rudolf	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Roche Diagnostics : Biomarkers - Abbott : heart failure device therapies - Astra Zeneca : heart failure pharmacotherapy - Bayer : heart failure pharmacotherapy - Novartis : heart failure pharmacotherapy

2022 ESC Guidelines on cardio-oncology - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
De Boer Rudolf	<p>2020</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : heart failure pharmacotherapy <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Abbott Laboratories : Biomarkers - Roche Diagnostics : Biomarkers - Astra Zeneca : heart failure pharmacotherapy - Boehringer-Ingelheim : heart failure pharmacotherapy - Novo-Nordisk : heart failure pharmacotherapy - Cardior Pharmaceuticals, GmbH : heart failure pharmacotherapy - Ionis Pharmaceuticals, Inc. : heart failure pharmacotherapy <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> - Membership of the American Heart Association (AHA), American College of Cardiology (ACC), and Dutch cardiac Society (NVVC) <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Novartis : failure pharmacotherapy - Abbott : Heart Failure - Astra Zeneca : heart failure pharmacotherapy - Bayer AG : heart failure pharmacotherapy

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
De Boer Rudolf	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Roche Diagnostics : Heart failure and oncology biomarkers - Astra Zeneca : heart failure pharmacotherapy - Novo Nordisk : Heart failure pharmacotherapy <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Roche Diagnostics : heart failure and oncology biomarkers - Abbott : Heart Failure devices - Astra Zeneca : heart failure pharmacotherapy - Novo-Nordisk : heart failure pharmacotherapy - Cardior GmbH : heart failure pharmacotherapy - Ionis Pharmaceuticals, Inc : heart failure pharmacotherapy <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> - President-elect of the Dutch Cardiac Society (NVVC)
Dent Susan	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Eli Lilly : breast cancer - Novartis : breast cancer <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Novartis : breast cancer

2022 ESC Guidelines on cardio-oncology - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Dent Susan	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Novartis : breast cancer</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself - Healthcare - IMAGING - stock options myocardial solutions < 2,000 Euros</p>
Farmakis Dimitrios T	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Bayer : Atrial fibrillation - Boehringer-Ingelheim : Atrial fibrillation, diabetes - Leo Pharma : Cancer - Orion Pharma : Heart failure</p> <hr/> <p>2021</p> <p>Financial Declaration</p> <p>- Abbott Laboratories : Biomarkers (troponin) - Leo Pharma : Cancer - Bayer : Heart failure - Boehringer-Ingelheim : Heart failure - Novartis : Heart failure</p>

2022 ESC Guidelines on cardio-oncology - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Gevaert Sofie	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : acute coronary syndromes, heart failure - Bristol Myers Squibb : Venous thrombosis
	<p>2021</p> <p>Nothing to be declared</p>
Gorog Diana	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Speaker fees - Boehringer-Ingelheim : Speaker fees
	<p>2021</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Astra Zeneca : Speaker fees - Boehringer-Ingelheim : Speaker fees <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Bayer AG : ACS - Alpha MD : ACS - Medtronic : TAVI

2022 ESC Guidelines on cardio-oncology - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Herrmann Joerg	<p>2020</p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Amgen Inc : Cardio-oncology - Mitobridge Inc : Ischemic heart disease <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Mitobridge : Ischemic Heart Disease
Lenihan Daniel	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Prothena : Amyloidosis - Eidos : Amyloidosis - Lilly : Cardiac Safety - Cytokinetics : Cardiac Safety - Clementia : Cardiac Safety - Astra Zeneca : Cardio-Oncology <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Myocardial Solutions : Cardio-Oncology

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Lenihan Daniel	<p>2020</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself - I am President of the International Cardio-Oncology Society</p>
	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Prothena : Amyloidosis - Eidos : Amyloidosis - Lilly : Cardiac Safety - Bristol Myers Squibb : Cardiac Safety - Cytokinetics : Cardiac Safety - Clementia : Cardiac Safety - Myocardial Solutions : Cardiac Safety - Astra Zeneca : Cardio-Oncology <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> - Myocardial Solutions : Cardio-Oncology <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself - I am Past President of the International Cardio-Oncology Society and I am on the Board of the Amyloidosis Foundation</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Lopez Fernandez Teresa	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Daiichi Sankyo : educational activities - Almirall Spain : educational online course organized by the Spanish Society of Cardiology and supported by an unrestricted grant by Almirall - Janssen-Cilag : online educational course - Roche Pharma : review article - Bayer : speaker fees <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Janssen-Cilag : online educational course - Philips : speaker fees - Incyte : speaker fees
Lyon Alexander	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Akcea : Cardiac Amyloidosis - Takeda Pharmaceuticals : Cardio-Oncology, Multiple Myeloma, Ixazomib - Pfizer : Cardiotoxicity of cancer drugs for renal cancer and chronic myeloid leukaemia: sunitinib, axitinib, bosutinib - GlaxoSmithKline : Heart Failure - Astra Zeneca : Heart Failure, Dapagliflozin - Novartis : Heart failure, Entresto, breast cancer - ribociclib, MPN - Ferring Pharmaceuticals : Prostate Cancer

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Lyon Alexander	<p>2020</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself</p> <ul style="list-style-type: none"> - Healthcare - HEART FAILURE - Stock option (<1%) in Heartfelt Technologies Inc Stock option (1%) in Brainstorm Inc Stock option (1%) in Myocardial Solutions Inc
	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Takeda Pharmaceuticals : Cardio-Oncology, Multiple Myeloma, Ixazomib - Pfizer : Cardiotoxicity of cancer drugs for renal cancer and chronic myeloid leukaemia: sunitinib, axitinib, bosutinib - GlaxoSmithKline : Heart Failure - Astra Zeneca : Heart Failure, Dapagliflozin - Novartis : Heart failure, Entresto, breast cancer - ribociclib, MPN - Ferring Pharmaceuticals : Prostate Cancer <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself</p> <ul style="list-style-type: none"> - Healthcare - HEART FAILURE - Stock option (<1%) in Heartfelt Technologies Inc Stock option (1%) in Brainstorm Inc Stock option (1%) in Myocardial Solutions Inc

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Moslehi Javid	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : basic cardiovascular research - Boehringer-Ingelheim : basic myocyte biology - Amgen Inc : basic myocyte biology - Astra Zeneca : cancer drugs <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> - American Heart Association (AHA) <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Advisory Board - Takeda Pharmaceuticals : Advisory Board - Bristol Myers Squibb : Advisory Board
Moura Brenda	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes- Dapagliflozin - Novartis : Heart failure- Sacubitril/valsartan

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Moura Brenda	2020 - Servier : heart failure- Sacubitril/valsartan - Boehringer-Ingelheim : Noac, Empagliflozin
	2021 Financial Declaration - Astra Zeneca : Diabetes- Dapagliflozin - Vifor Pharma : Heart failiure - Bayer : heart failure - Servier : heart failure- Sacubitril/valsartan - Boehringer-Ingelheim : Noac, Empagliflozin
Salinger Sonja	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Bayer : Atrial fibrillation - Pfizer : Atrial fibrillation - Astra Zeneca : Heart Faillure
	2021 Financial Declaration - Bayer : Atrial fibrillation - Pfizer : Atrial fibrillation - Astra Zeneca : Heart Faillure
Stephens Richard	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - BMC : Medical publishing

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Stephens Richard	<p>2020</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Several : I receive expenses for travel from many sources, as an independent patient advocate and conference speaker.</p> <p>Research funding (personal) from healthcare industry.For yourself - Several : I receive honoraria from rsearch grants or budgets for my work as an independent patient advocate</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself - I am an independent patient advocate and in the past that has involved consultancy work with industry and charities and government bodies. I do not hold any such posts or roles currently.</p>
	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - BMC : Medical publishing</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Several : I receive expenses for travel from many sources, mostly academic or charity but sometimes commercial, as an independent patient advocate and conference speaker.</p> <p>Research funding (personal) from healthcare industry.For yourself - Several : I receive honoraria from rsearch grants or budgets for my work as an independent patient advocate</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself - I am an independent patient advocate and in the past that has involved paid consultancy work with industry and charities and government bodies. I do not hold any such posts or roles currently.</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Suter Thomas	<p>2020</p> <p>Nothing to be declared</p>
	<p>2021</p> <p>Nothing to be declared</p>
Szmit Sebastian	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Amgen : cardio-oncology - Astra Zeneca : cardio-oncology - Bayer : cardio-oncology - Angelini : cardio-oncology - Teva Pharmaceutical Industries : cardio-oncology - Bristol-Myers Squibb : cardio-oncology - Reynolds Medical Diagnostyka Kardiologiczna sp. z o.o. : cardio-pulmonary exercise test <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> - Investigator of the CARAVAGGIO trial and the API-CAT study
	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : cardio-oncology - Pfizer : cardio-oncology

2022 ESC Guidelines on cardio-oncology - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Szmit Sebastian	<p>2021</p> <ul style="list-style-type: none"> - Gilead : cardio-oncology - Angelini : cardio-oncology <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> - Investigator of the API-CAT study
Tamargo Juan Luis	<p>2020</p> <p>Nothing to be declared</p>
	<p>2021</p> <p>Nothing to be declared</p>
Thavendiranathan P	<p>2020</p> <p>Nothing to be declared</p>
	<p>2021</p> <p>Nothing to be declared</p>
Tocchetti Carlo Gabriele	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Amgen : Herat Failure, enrollment of patients in the Galactic trial

2022 ESC Guidelines on cardio-oncology - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Tocchetti Carlo Gabriele	<p>2020</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> - Canadian Patent No. 2,613,477, issued on Dec 3, 2013 Inventors: Nazareno Paolucci, David A Kass, Carlo G Tocchetti. Owner: Johns Hopkins University Entitled: THIOL-SENSITIVE POSITIVE INOTROPES JHU Ref.: C04755-P04755-05 P75NTR ANTAGONISTS AND TREATMENT OF ACUTE AND CHRONIC CARDIAC DISEASE. Inventors: Paolucci; Nazareno; (Baltimore, MD) ; Feng; Ning; (Baltimore, MD) ; Tocchetti; Carlo G.; (Baltimore, MD) ; Takahashi; Cyrus; (Baltimore, MD) ; Carter; Bruce; (Nashville, TN). 2018. Source of the Document: United States Patent and Trademark Office Pre-Granted Publication. Patent number US20180271931, Publication date: Sep 27, 2018
	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Vivalyfe : Dyslipidemia <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Amgen : Herat Failure, enrollment of patients in the Galactic trial <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> - Canadian Patent No. 2,613,477, issued on Dec 3, 2013 Inventors: Nazareno Paolucci, David A Kass, Carlo G Tocchetti. Owner: Johns Hopkins University Entitled: THIOL-SENSITIVE POSITIVE INOTROPES JHU Ref.: C04755-P04755-05 P75NTR ANTAGONISTS AND TREATMENT OF ACUTE AND CHRONIC CARDIAC DISEASE. Inventors: Paolucci; Nazareno; (Baltimore, MD) ; Feng; Ning; (Baltimore, MD) ; Tocchetti; Carlo G.; (Baltimore, MD) ; Takahashi; Cyrus; (Baltimore, MD) ; Carter; Bruce; (Nashville, TN). 2020. Patent office: United States Patent and Trademark Office Granted Publication. Patent number US10786543, Publication date: Sep 29, 2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Van Der Meer Peter	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Vifor International : comorbidities in Heart Failure - Pharma Nord : selenium supplements in HF <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Pharmacosmos : iron deficiency - Vifor International : iron deficiency and hyperkalemia - Novartis : Sacubitril/valsartan - Boehringer-Ingelheim : sglT2 inhibitors <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Pfizer : amyloidosis - Astra Zeneca : drugs for heart failure - Vifor International : iron deficiency and hyperkalemia
	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Vifor International : comorbidities in Heart Failure - Pharma Nord : selenium supplements in HF <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : amyloidosis

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Van Der Meer Peter	<p>2021</p> <ul style="list-style-type: none"> - Novo-Nordisk : diabetes and heart failure - Pharmacosmos : iron deficiency - Vifor International : iron deficiency and hyperkalemia - Novartis : Sacubitril/valsartan - Boehringer-Ingelheim : sglT2 inhibitors <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Pfizer : amyloidosis - Astra Zeneca : drugs for heart failure - Pharma Nord : food supplements - Vifor International : iron deficiency and hyperkalemia
van der Pal Helena Johanna	<p>2020</p> <p>Nothing to be declared</p>
	<p>2021</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer AG : Advisory board fees - Astra Zeneca : speaker fees - Boehringer-Ingelheim : speaker fees - Novartis : speaker fees
Abid Leila	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Novo-Nordisk : diabetes - Abbott : hypertension - Boehringer-Ingelheim : hypertension - Novartis : hypertension - Servier : hypertension - Sanofi Aventis : hypertension - Menarini : hypertension <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Sanofi Aventis : aprovasc - Novartis : exforge - Abbott : odrik

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer Healthcare : Antithrombotic therapies - Novo-Nordisk : Diabetes - Astrazeneca : Diabetes - Boehringer Ingelheim : Diabetes <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> - Member of the French Society of Cardiology
Ahmed Tarek	<p>2021</p> <p>Nothing to be declared</p>
Alayed Ahmad	<p>2021</p> <p>Nothing to be declared</p>
Aleman Berthe Mauricia Pauline	<p>2021</p> <p>Nothing to be declared</p>
Alexandre Joachim	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Biotronik : medical device - Bioserenity : medical device - Bayer Healthcare : pharmacological advice on Bayer products

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Alexandre Joachim	<p>2021</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Bayer Healthcare : 2021 ESC congress</p>
Andersen Karl	<p>2021</p> <p>Nothing to be declared</p>
Andrushchuk Uladzimir	<p>2021</p> <p>Nothing to be declared</p>
Barac Ana	<p>2021</p> <p>Nothing to be declared</p>
Benlamin Hisham	<p>2021</p> <p>Nothing to be declared</p>
Benyass Aatif	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Novartis : heart failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Sanofi Aventis : Arterial Hypertension</p>
Borger Michael A	<p>2021</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Cryolife : aortic surgery - Abbott : heart valve therapy - Edwards Lifesciences : heart valve therapy</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Borger Michael A	2021 - Medtronic : heart valve therapy
Bosevski Marijan	2021 Nothing to be declared
Briasoulis Alexandros	2021 Nothing to be declared
Bursacovschi Daniela	2021 Nothing to be declared
Casado Arroyo Ruben	2021 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - St Jude Medical : speaker educational fees - Johnson & Johnson : speaker educational fees
Cautela Jennifer	2021 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Bristol Myers Squibb : Cardio-oncology - Novartis : Heart Failure - Sanofi Aventis : Heart failure - Janssen-Cilag : Ibrutinib

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Celutkiene Jelena	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Pfizer : anticoagulation - Boehringer-Ingelheim : heart failure - Novartis : heart failure - Bayer Healthcare : heart failure - Astrazeneca : heart failure
Cikes Maja	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Pfizer : Amyloidosis - GE Healthcare : Cardiovascular ultrasound - Amicus Therapeutics : Fabry disease - Astra Zeneca : Heart failure - Bayer : Heart failure - Boehringer-Ingelheim : Heart failure - Teva Pharmaceutical Industries : Heart failure - Krka Pharma : Heart failure - Llvanova : Heart failure - Novartis : Heart failure, hyperlipidaemia

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cikes Maja	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - CorVia : Heart failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Pfizer : Amyloidosis - Abbott : Heart failure - Novartis : Heart failure
Cohen-Solal Alain	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Impulse Dynamics : Hear Failure - Bayer AG : Heart Failure - Cytokinetics : Heart Failure - Astra Zeneca : HF - Novartis : HF - Servier : HF - Sanofi Aventis : HF - Abbott Laboratories : HF - Vifor International : HF - Merck Sharp & Dohme : HF - CVRx : HF - Leo Pharma : Thrombosis

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Czuriga Daniel	<p>2021</p> <p>Nothing to be declared</p>
Dhiman Kreena	<p>2021</p> <p>Nothing to be declared</p>
Economides Evagoras	<p>2021</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Novartis : Speaker fees <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Bayer : Conference in Athens, Greece, October 2021
Ederhy Stephane	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Amgen : Pharmaceutical Industry - Pfizer : Pharmaceutical Industry - Pierre-Fabre : pharmaceutical industry - Ipsen : Pharmaceutical Industry - BMS : Pharmaceutical Industry
Edvardsen Thor	<p>2021</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Fauchier Laurent	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Healthcare - Bayer : Healthcare - Boehringer-Ingelheim : Healthcare - Medtronic : Healthcare - Novartis : Healthcare - BMS/Pfizer : Healthcare - Novo-Nordisk : Healthcare - Zoll Medical : Healthcare - XO : Healthcare
Fiuza Maria Manuela	<p>2021</p> <p>Nothing to be declared</p>
Foscoli Marina	<p>2021</p> <p>Nothing to be declared</p>
Fradley Michael	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : cardiooncology - Takeda Pharmaceuticals : cardiooncology - Myovant : cardiooncology - Abbott : electrophysiology

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Fradley Michael	<p>2021</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Medtronic : electrophysiology and cardiooncology</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - American College of Cardiology; American Heart Association; Heart Rhythm Society; International CardioOncology Society</p>
Gerber Bernhard Lothar Marie	<p>2021</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Belgian Society of Cardiology</p>
Grapsa Julia	<p>2021</p> <p>Nothing to be declared</p>
Gulati Geeta	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Orion : Cardio-Oncology - Roche Pharma : Cardio-Oncology</p>
Halvorsen Sigrun	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Boehringer-Ingelheim : anticoagulation -speaker fee - Bristol Myers Squibb : Anticoagulation- speaker fee - Novartis : heart failure - speaker fee</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Heuser Michael	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Novartis : Leukemia - Pfizer : Leukemia - Takeda Pharmaceuticals : Leukemia - Bristol Myers Squibb : Leukemia - WebMD : Leukemia - AbbVie : Leukemia - Jazz Pharmaceuticals : Leukemia - PinotBio : Leukemia - Agios Pharmaceuticals : Leukemia - Kura Oncology : Leukemia - Eurocept : Leukemia <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Astellas : Clinical trial - Daiichi Sankyo : Leukemia - Novartis : Leukemia - AbbVie : Leukemia - Jazz Pharmaceuticals : Leukemia - BergenBio : Leukemia - Loxo Oncology : Leukemia

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Hubbert Laila	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : speakers fee webinar - Astellas : speakers fee webinar - Orion Pharma : speakers fee webinar
Humbert Marc	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Novartis : Asthma - Sanofi Aventis : Asthma - Astra Zeneca : Asthma, COPD - GlaxoSmithKline : Asthma, COPD - Chiesi Pharma : Pulmonary hypertension, asthma, COPD - Johnson & Johnson : Pulmonary hypertension: Bosentan, Macitentan, Epoprostenol, Selexipag - Bayer : Pulmonary hypertension: Riociguat - Merck Sharp & Dohme : Pulmonary hypertension: Riociguat - Altavant : Pulmonary hypertension: Rodatristat - Acceleron : Pulmonary hypertension: Sotatercept - Shou Ti : Pulmonary hypertension: translational research - Morphogenics : Pulmonary hypertension: translational research - Ferrer Internacional : Pulmonary hypertension: Treprostinil - AOP Orphan Pharmaceuticals : Pulmonary hypertension: Treprostinil

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Humbert Marc	<p>2021</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Johnson & Johnson : Pulmonary hypertension translational research - Merck Sharp & Dohme : Pulmonary hypertension translational research - Acceleron : Pulmonary hypertension translational research - Shou Ti : Pulmonary hypertension translational research
Iakobishvili Zaza	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Pfizer : Amyloidosis - Pfizer : Atrial fibrillation - Astra Zeneca : Diabetes - Boehringer-Ingelheim : Diabetes, atrial fibrillation - Novo-Nordisk : Diabetes, Obesity - Sanofi Aventis : Hyperlipidemia - Bayer : PAD <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> - Novo-Nordisk : Diabetes
Iovino Alessandra	<p>2021</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Jaarsma Tiny	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Boehringer-Ingelheim : heart failure</p>
Jurcut Ruxandra Oana	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Astra Zeneca : Dapagliflozin - Pfizer : Eliquis, Tafamidis - Genzyme : Fabrazyme - Novartis : Inclisiran, Sacubitril/valsartan - Genesys : Migalastat - Servier : Prestarium - Bayer AG : Xarelto</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Astra Zeneca : Dapagliflozin</p>
Kahan Thomas	<p>2021</p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Medtronic : Renal denervation - Recor : Renal denervation</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kalejs Oskars	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiovascula Pharmacotherapy - Boehringer-Ingelheim : Cardiovascular Pharmacotherapy - Pfizer : Cardiovascular Pharmacotherapy - Berlin Menarini : Cardiovascular Pharmacotherapy - Bayer AG : Cardiovascular Pharmacotherapy.
Kinova Elena	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Pfizer : amyloidosis - Berlin Chemie AG : Echocardiography - Gedeon Richter : Echocardiography - Infinita : Echocardiography - Bayer : principal investigator - Astra Zeneca : SGLT2 inhibitors
Konradi Aleksandra	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Novartis : hypertension - Krka Pharma : hypertension

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Konradi Aleksandra	<p>2021</p> <ul style="list-style-type: none"> - Gedeon Richter : hypertension - Servier : hypertsnion
Koskinas Konstantinos	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Amgen : Cardiology - Daiichi Sankyo : Cardiology <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Novartis : Cardiology
Kotecha Dipak	<p>2021</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer : Data Science (Advisory Board) - Amomed : Data Science (Advisory Board) - Protherics Medicines Development : Data Science (Advisory Board) - MyoKardia : Trial Advisory Board <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Bayer : Funding for ESC STEEER-AF trial - Boston Scientific : Funding for ESC STEEER-AF trial - Daiichi Sankyo : Funding for ESC STEEER-AF trial - Boehringer Ingelheim : Funding for ESC STEEER-AF trial - BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p>2021</p> <ul style="list-style-type: none"> - Amomed : Systematic review - Protherics Medicines Development : Systematic review <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> - Grants from the UK National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).
Kurmann Reto Daniel	<p>2021</p> <p>Nothing to be declared</p>
Ky Bonnie	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - UpToDate : Cardio-Oncology - Pfizer : Cardio-Oncology (consulting) <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Pfizer : Cardio-Oncology - Impulse Dynamics : Heart Failure <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> - American College of Cardiology American Heart Association
Lancellotti Patrizio	<p>2021</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Amgen : Speaker fee - Novartis : Speaker fee - Sanofi Aventis : Speaker fee - Bayer AG : Speaker fee <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Novartis : Lipid Cardio Study - Amgen : Research grant - Bayer AG : Research Grant
Laredj Nadia	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Servier : hypertension <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Sanofi Aventis : hypertension in international congress of cardiology of CHU oran
Leszek Przemyslaw	<p>2021</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Heart Failure

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Leszek Przemyslaw	<p>2021</p> <ul style="list-style-type: none"> - Bayer : Heart Failure - Boehringer-Ingelheim : Heart Failure - Pfizer : Heart Failure - Servier : Heart Failure - Roche Diagnostics : Heart Failure <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Servier : Heart Failure
Lewis Basil S	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Idorsia : Antithrombotics - Kowa : Lipidology - CSL Behring : Lipidology, Secondary prevention <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Kowa : Lipidology
Lip Gregory Yh	<p>2021</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Daiichi-Sankyo : Anticoagulation - Boehringer Ingelheim : Anticoagulation; Registries; Steering Committees - Pfizer : Anticoagulation; Registries - BMS : Antithrombotic therapy

2022 ESC Guidelines on Cardio-Oncology - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Lip Gregory Yh	<p>2021</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Boehringer-Ingelheim : AF registries [unrestricted educational grant]</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself - Shares in private limited company (a legal separate entity in UK), but no salary/dividends/income/personal remuneration received.</p>
Lipar Luka	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Astra Zeneca : DAPT - Servier : Ischemic heart disease - Berlin Menarini : Ischemic heart disease - Bayer : OAC</p>
Lochen Maja-Lisa	<p>2021</p> <p>Nothing to be declared</p>
Malaczynska-Rajpold Katarzyna	<p>2021</p> <p>Nothing to be declared</p>
Manintveld Olivier	<p>2021</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Manisty Charlotte	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Pfizer : Cardio-oncology</p>
Martin Garcia Ana	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Daiichi Sankyo : Thrombosis</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Menarini : Spanish virtual cardiology congress</p>
Metra Marco	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Astra-Zeneca : Advisory boards fee and speaker's fees - Boehringer-Ingelheim : As member of advisory boards - Actelion : As member of Data Monitoring Committee of SERENADE trial - Llvanova : Data Monitoring Committee member - Vifor Pharma : Executive committee member of AFFIRM -AHF and DIAMOND-HF trial - Amgen : Member of the Executive committee of one trial, GALACTIC-HF - Abbott Vascular : Speaker's fees - Edwards Therapeutics : Speaker's fees</p>

2022 ESC Guidelines on Cardio-Oncology - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mindham Richard	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself - I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>
Mirrakhimov Erkin	<p>2021</p> <p>Nothing to be declared</p>
Moonen Marie	<p>2021</p> <p>Nothing to be declared</p>
Moore Alice May	<p>2021</p> <p>Nothing to be declared</p>
Neilan Tomas	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Roche Pharma : Cardio-Onc - Bristol Myers Squibb : Cardio-Onc - H3Biomedicine : Cardio-onc - Genentech : COVID-19</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Neilan Tomas	<p>2021</p> <ul style="list-style-type: none"> - AbbVie : COVID-19 - Intrinsic Imaging : Imaging <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardio Onc
Nesukay Elena	<p>2021</p> <p>Nothing to be declared</p>
Nielsen Jens Cosedis	<p>2021</p> <p>Nothing to be declared</p>
Nielsen Kirsten Melgaard	<p>2021</p> <p>Nothing to be declared</p>
Pagava Zurab	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Berlin Chemie AG (Georgia) : Spieker fees - Servier (Georgia) : Spieker fees - AstraZeneca (Georgia) : Spieker fees <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Pfizer : Spieker fees
Parrini Iris	<p>2021</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Petronio Anna Sonia	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Abbott : Structural Heart Disease - Boston Scientific : Structural Heart Disease <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Medtronic : Structural Heart Disease <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Abbott : structural heart disease - Boston Scientific : Structural heart disease - Medtronic : Structural Heart disease
Pillana Pruthi Edita	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Krka Pharma : Hypertension and Dyslipidemia
Prescott Eva	<p>2021</p> <p>Nothing to be declared</p>
Pudil Radek	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Roche Diagnostics : Biomarkers and its use in dg. of CV diseases

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Pudil Radek	<p>2021</p> <ul style="list-style-type: none"> - Astra Zeneca : lectures - topic: educational area - diagnosis and treatment of heart failure - Bayer : lectures - topic: educational area - diagnosis and treatment of heart failure - Novartis : lectures - topic: educational area - diagnosis and treatment of heart failure
Rainer Peter	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Novartis : Education - Vifor Pharma : Education
Rakisheva Amina	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer : Atrial Fibrillatuion - Novartis : Heart Failure
Rassaf Tienush	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Anticoagulation - Berlin Chemie AG : Anticoagulation - Bayer Vital and Bayer Healthcare : Anticoagulation, heart failure, heart-brain-interaction - Novartis : Heart Failure - Daiichi Sankyo : Lipids, anticoagulation - Abiomed : myocardial infarction

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Rassaf Tienush	<p>2021</p> <ul style="list-style-type: none"> - Medtronic : Valve therapy <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Valve therapy <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> - I am member of the advisory board of the German Heart Foundation
Salem Joe Elie	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiotoxicity of anticancer drugs - Novartis : Cardiotoxicity of anticancer drugs - Bristol Myers Squibb : Cardiotoxicity of anticancer drugs <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> - Novartis : Cardiotoxicity of anticancer drugs - Bristol Myers Squibb : Cardiotoxicity of anticancer drugs
Samadov Fuad	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Servier : Coronary artery disease - Novartis : Heart failure

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Samardzic Jure	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation - Servier : Coronary Artery Disease - Berlin Chemie AG : Coronary Artery Disease - Sanofi Aventis : Heart failure - Novartis : Hypertension - Krka Pharma : Hypertension
Savarese Gianluigi	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Teva Pharmaceutical Industries : Diabetes - Cytokinetics : Heart Failure - Astra Zeneca : RWE <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Bayer : Heart Failure - Merck Sharp & Dohme : Heart Failure
Selimovic Mirsad	<p>2021</p> <p>Nothing to be declared</p>
Simic Dragan	<p>2021</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Sitges Marta	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Abbott : Heart Valve Disease - Edwards Lifesciences : Heart Valve Disease - Medtronic : Heart Valve Disease <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Abbott : Heart Valve Disease - Edwards Lifesciences : Heart Valve Disease <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Atrial Fibrillation - Menarini : Continuous Education on Cardiovascular Diseases - Novartis : Heart Failure - Rovi : Heart Failure - Amgen : Hypercholesterolemia - Merck Sharp & Dohme : Hypercholesterolemia
Skouri Hadi	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Speaker fee, Honoraria; advisory board fees - Boehringer-Ingelheim : Speaker fee, Honoraria; advisory board fees - Novartis : Speaker fee, Honoraria; advisory board fees

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Skouri Hadi	<p>2021</p> <ul style="list-style-type: none"> - Pfizer : Speaker fee, Honoraria; advisory board fees - Servier : Speaker fee, Honoraria; advisory board fees - Abbott : Speaker fee, Honoraria; advisory board fees and proctoring
Slanina Miroslav	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Novartis : Chronic heart failure - Servier : chronic heart failure and arterial hypertension <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Novartis : chronic hear failure
Smyth Yvonne	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Vifor International : Ad board - Astra Zeneca : Speaker fees - Daiichi Sankyo : Speaker fees - Novartis : Speaker fees - Bayer : Speaker fees, advisory board fees <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.For yourself</p> <ul style="list-style-type: none"> - Cardiologist at University Hospital, Bon Secours Hospital Galway

2022 ESC Guidelines on Cardio-Oncology - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Srojedinova Nigora	<p>2021</p> <p>Nothing to be declared</p>
ten Berg Jurrien M	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : ACS - Boehringer-Ingelheim : ACS - Ferrer Internacional : ACS - Bayer : AF - Pfizer : AF
Thuny Franck	<p>2021</p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Congress
Touyz Rhian	<p>2021</p> <p>Nothing to be declared</p>
Tuohinen Suvi	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Abbott : TriClip, tricuspidal imaging, echocardiography, transesophageal echocardiography

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Tycinska Agnieszka	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Pfizer, Astra Zeneca, Orion Pharma, Bayer, Servier : AF, CCS, AHF - Novartis : HF - Krka Pharma : Prevention
Vasyuk Yury	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Moscow State University of Medicine and Dentistry : Internal diseases, cardiology
Vettus Riina	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer : speaker fees Anticoagulation - Servier Laboratories : speaker fees Anticoagulation - SIA Novartis Baltics : speaker fees Heart failure
Wilhelm Matthias	<p>2021</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : CV drugs - Novartis : CV drugs - Boehringer-Ingelheim : CV drugs

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Wilhelm Matthias	<p>2021</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Foundation board member Swiss Heart Foundation</p>
Zaliaduonyte Diana	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Astra Zeneca : speaker - Boehringer-Ingelheim : speaker - Novartis : speaker</p>
Zamorano Gomez Jose Luis	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Bayer AG : HF - Myostrain : MRI - Abbott : Valve - Edwards Lifesciences : Valve</p>
Zelveian Parounak	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Novartis : Heart failure - Pfizer : Hypertension & IHD</p>

2022 ESC Guidelines on Cardio-Oncology - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Zelveian Parounak	2021 <ul style="list-style-type: none"> - Egis Pharma : Hypertension & IHD - Recordati International : Hypertension & IHD - Krka Pharma : Hypertension & IHD - Grindex Pharma : Hypertension & IHD
Zorkun Cafer	2021 Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer AG : Advisory board fees - Astra Zeneca : speaker fees - Boehringer-Ingelheim : speaker fees - Novartis : speaker fees <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Bayer AG : Advisory board fees - Astra Zeneca : speaker fees - Boehringer-Ingelheim : speaker fees - Novartis : speaker fees
Aboyans Victor	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer Healthcare : Antithrombotic therapies - Bristol Myers Squibb : Antithrombotic therapies - Astrazeneca : Diabetes <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Bayer Healthcare : Peripheral Artery Disease

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer Healthcare : Antithrombotic therapies - Novo-Nordisk : Diabetes - Astrazeneca : Diabetes - Boehringer Ingelheim : Diabetes <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> - Member of the French Society of Cardiology
Antoniou Sotiris	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Pfizer : speaker fees for education - AF - Bayer AG : speaker fees for education - AF - Daiichi Sankyo : speaker fees for education -AF - Astra Zeneca : speaker fees for education - CVD <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Joint working initiative on improving CV care

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Antoniou Sotiris	<p>2020</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of Arrhythmia alliance medical advisory panel</p> <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Pfizer : speaker fees for education - AF - Bayer AG : speaker fees for education - AF - Daiichi Sankyo : speaker fees for education -AF - Astra Zeneca : speaker fees for education - CVD - Boehringer-Ingelheim : speaker fees for education - CVD</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Astra Zeneca : Joint working initiative on improving CV care</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of Arrhythmia alliance medical advisory panel</p>
Arbelo Elena	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Biosense Webster : Atrial fibrillation</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Arbelo Elena	<p>2021</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Biosense Webster : Atrial fibrillation
Asteggiano Riccardo	<p>2020</p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.For yourself</p> <ul style="list-style-type: none"> - Springer Nature Switzerland AG, : IB323946 Royalties Earned Current Period Royalties Due 1: Cardiac Management of Oncology Patients Edition 1 266979
	<p>2021</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Council of Cardio-Oncology ESC : cardio-oncology
Baigent Colin	<p>2020</p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Cardiovascular and renal disease
	<p>2021</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Renal disease
Baumbach Andreas	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Pharmacology - CERC : Research Organisation: Events Committees - Abbot Vascular : Stents - Microport : Stents

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Baumbach Andreas	<p>2020</p> <ul style="list-style-type: none"> - Sinomed : Stents - Venus Medtech : Valves, CEP
	<p>2021</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet - Faraday : Infarct size reduction - Microport : Stents - Sinomed : Stents - Medtronic : Valves - Pi-Cardia : Valves <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> - Abbot Vascular : OCT
Borger Michael A	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Cryolife : aortic surgery - Abbott : heart valve therapy - Edwards Lifesciences : heart valve therapy - Medtronic : heart valve therapy
	<p>2021</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Cryolife : aortic surgery - Abbott : heart valve therapy - Edwards Lifesciences : heart valve therapy

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Borger Michael A	<p>2021</p> <ul style="list-style-type: none"> - Medtronic : heart valve therapy
Celutkiene Jelena	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Pfizer : anticoagulation - Amgen : heart failure - Boehringer-Ingelheim : heart failure - Novartis : heart failure - Bayer Healthcare : heart failure - Astrazeneca : heart failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Roche Diagnostics : heart failure <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Pfizer : anticoagulation - Boehringer-Ingelheim : heart failure - Novartis : heart failure - Bayer Healthcare : heart failure - Astrazeneca : heart failure

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cikes Maja	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation - Pfizer : Anticoagulation, amyloidosis - Astra Zeneca : coronary heart disease - Astra Zeneca : Heart Failure - Boehringer-Ingelheim : Heart failure - Novartis : Heart failure - Orion : Heart failure - Teva Pharmaceutical Industries : Heart failure <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Novartis : heart failure - CorVia : Heart failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Abbott : Heart failure - Novartis : Heart failure
	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Pfizer : Amyloidosis - GE Healthcare : Cardiovascular ultrasound

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cikes Maja	<p>2021</p> <ul style="list-style-type: none"> - Amicus Therapeutics : Fabry disease - Astra Zeneca : Heart failure - Bayer : Heart failure - Boehringer-Ingelheim : Heart failure - Teva Pharmaceutical Industries : Heart failure - Krka Pharma : Heart failure - Llvanova : Heart failure - Novartis : Heart failure, hyperlipidaemia <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - CorVia : Heart failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Pfizer : Amyloidosis - Abbott : Heart failure - Novartis : Heart failure
Collet Jean-Philippe	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Amgen : Lipids - Astra Zeneca : Post-PCI antiplatelet treatment - Bristol Myers Squibb : Post-TAVR antithrombotic treatment <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Boston Scientific : Post-TAVR antithrombotic treatment

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p>2020 - Bristol Myers Squibb : Post-TAVR antithrombotic treatment</p> <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : post PCI antithrombotic therapy - Pfizer : POST PCI ANTITHROMBOTIC THERAPY - Terumo Inc : POST PCI ANTITHROMBOTIC THERAPY - Bristol Myers Squibb : Post-TAVI antithrombotic treatments <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Medtronic : post tavi antithrombotic therapy - Bristol Myers Squibb : post-tavi antithrombotic therapy
Falk Volkmar	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Berlin Heart : Advisory - Novartis : Consultancy - Abbott : Educational Grant for HCP's - Edwards Lifesciences : Educational Grant for HCP's - Medtronic : Educational Grant for HCP's - Cryolife / Jotec : Educational Grant for HCP's

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Falk Volkmar	<p>2021</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Berlin Heart : Advisory - Novartis : Consultancy - Abbott : Educational Grant for HCP's - Edwards Lifesciences : Educational Grant for HCP's - Medtronic : Educational Grant for HCP's - Cryolife / Jotec : Educational Grant for HCP's - Boston Scientific : Study - Biotronik : Study - Liva Nova : Study
Fauchier Laurent	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Bayer : Healthcare - Boehringer-Ingelheim : Healthcare - Medtronic : Healthcare - Novartis : Healthcare - BMS/Pfizer : Healthcare - XO : Healthcare <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Astra Zeneca : Healthcare - Bayer : Healthcare

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Fauchier Laurent	<p>2021</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Healthcare - Medtronic : Healthcare - Novartis : Healthcare - BMS/Pfizer : Healthcare - Novo-Nordisk : Healthcare - Zoll Medical : Healthcare - XO : Healthcare
Gale Christopher Peter	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : acs hf <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : af - Abbott : diabetes <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Amgen : ACS - Chiesi Pharma : ACS - Astra Zeneca : ACS Hf - Boehringer-Ingelheim : AF - Daiichi Sankyo : AF - Menarini : CAD

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<p>2021</p> <ul style="list-style-type: none"> - Bayer : CVD - Zydus : CVD - Oxford University Press : EHJQCCO <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : AF - Abbott : Diabetes - European Society of Cardiology : EuroHeart <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.For yourself</p> <ul style="list-style-type: none"> - Wondrmedical
Halvorsen Sigrun	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Anticoagulation - Sanofi Aventis : Lipidlowering <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation - Pfizer : Anticoagulation - Novartis : Heart failure

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulation -speaker fee - Bristol Myers Squibb : Anticoagulation- speaker fee - Novartis : heart failure - speaker fee
Iung Bernard	<p>2020</p> <p>Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Nothing to be declared</p>
Jaarsma Tiny	<p>2020</p> <p>Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : heart failure
Konradi Aleksandra	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Novartis : hypertension - Krka Pharma : hypertension - Gedeon Richter : hypertension

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Konradi Aleksandra	2020 - Servier : hypertsniion
	2021 Financial Declaration - Novartis : hypertension - Krka Pharma : hypertension - Gedeon Richter : hypertension - Servier : hypertsniion
Koskinas Konstantinos	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Amgen : Cardiology - Daiichi Sankyo : Cardiology Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Novartis : Cardiology
	2021 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Amgen : Cardiology - Daiichi Sankyo : Cardiology Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Novartis : Cardiology

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer : Data Science (Advisory Board) - Amomed : Data Science (Advisory Board) - Protherics Medicines Development : Data Science (Advisory Board) <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Bayer : Funding for ESC STEEER-AF trial - Boston Scientific : Funding for ESC STEEER-AF trial - Daiichi Sankyo : Funding for ESC STEEER-AF trial - Boehringer Ingelheim : Funding for ESC STEEER-AF trial - BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial - Amomed : Systematic review <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> - Grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR HTA-130280 DaRe2THINK), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).
	<p>2021</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer : Data Science (Advisory Board)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p>2021</p> <ul style="list-style-type: none"> - Amomed : Data Science (Advisory Board) - Protherics Medicines Development : Data Science (Advisory Board) - MyoKardia : Trial Advisory Board <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Bayer : Funding for ESC STEEER-AF trial - Boston Scientific : Funding for ESC STEEER-AF trial - Daiichi Sankyo : Funding for ESC STEEER-AF trial - Boehringer Ingelheim : Funding for ESC STEEER-AF trial - BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial - Amomed : Systematic review - Protherics Medicines Development : Systematic review <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> - Grants from the UK National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).
Landmesser Ulf	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer AG : Advisory Board fee - Amgen : Speaker fee - Novartis : Speaker fee

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p>2020</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Novartis : Lipid Cardio Study - Bayer AG : Research Grant <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Amgen : Speaker fee - Novartis : Speaker fee - Sanofi Aventis : Speaker fee - Bayer AG : Speaker fee <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Novartis : Lipid Cardio Study - Amgen : Research grant - Bayer AG : Research Grant
Lewis Basil S	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Vifor International : Heart failure - Kowa : Lipidology - CSL Behring : Lipidology, Secondary prevention

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Lewis Basil S	<p>2020</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Kowa : Lipidology
	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Idorsia : Antithrombotics - Kowa : Lipidology - CSL Behring : Lipidology, Secondary prevention <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Kowa : Lipidology
Linhart Ales	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Servier : Arterial hypertension, coronary heart disease, heart failure - Boehringer-Ingelheim : Atrial fibrillation, diabetes - Sanofi Aventis : Fabry disease - Takeda Pharmaceuticals : Fabry disease
	<p>2021</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Servier : Arterial hypertension, coronary heart disease, heart failure - Boehringer-Ingelheim : Atrial fibrillation, diabetes

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Linhart Ales	<p>2021</p> <ul style="list-style-type: none"> - Sanofi Aventis : Fabry disease - Takeda Pharmaceuticals : Fabry disease - Avrobio : Faby disease - Novartis : Heart failure
Lochen Maja-Lisa	<p>2020</p> <p>Nothing to be declared</p>
	<p>2021</p> <p>Nothing to be declared</p>
Mindham Richard	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Imperial College, London : 3 honoraria totalling GB£500/€550, passed in full to UK charity, CardiomyopathyUK. There will be no more honoraria. <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> - I support actively the British charity CardiomyopathyUK and make a monthly payment to support their activites. I also passed the three honoraria in 2A to CardiomyopathyUK, in full. <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> - Re item 7A: I have shares which are held inside and outside of a pension. I am unaware of what the shares are as they are all managed by a portfolio manager. Consequently I do not know whether I hold any shares in healthcare or healthcare-related companies, or in media or education companies.

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mindham Richard	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself - I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>
Nielsen Jens Cosedis	<p>2020</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of Danish Heart Foundation</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself - I received institutional research grants from the Novo Nordisk Foundation</p> <hr/> <p>2021</p> <p>Nothing to be declared</p>
Petersen Steffen Erhard	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p>2020</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. For yourself - Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</p>
	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. For yourself - Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</p>
Prescott Eva	<p>2020</p> <p>Nothing to be declared</p>
	<p>2021</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Rakisheva Amina	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer : Atrial Fibrillatuion - Novartis : Heart Failure <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Bayer : Atrial Fibrillatuion - Novartis : Heart Failure
Sitges Marta	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Abbott : Heart Valve Disease - Edwards Lifesciences : Heart Valve Disease - Medtronic : Heart Valve Disease <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Abbott : Heart Valve Disease - Edwards Lifesciences : Heart Valve Disease <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Atrial Fibrillation - Menarini : Continous Education on Cardiovascular Diseases - Novartis : Heart Failure - Merck Sharp & Dohme : Hypercholesterolemia

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Sitges Marta	<p>2021</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Abbott : Heart Valve Disease - Edwards Lifesciences : Heart Valve Disease - Medtronic : Heart Valve Disease <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Abbott : Heart Valve Disease - Edwards Lifesciences : Heart Valve Disease <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Atrial Fibrillation - Menarini : Continous Education on Cardiovascular Diseases - Novartis : Heart Failure - Rovi : Heart Failure - Amgen : Hypercholesterolemia - Merck Sharp & Dohme : Hypercholesterolemia
Touyz Rhian	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Novartis : Consultancy-expert opinion <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Nothing to be declared</p>